IL192800A - 2fgf binding peptides and their use - Google Patents

2fgf binding peptides and their use

Info

Publication number
IL192800A
IL192800A IL192800A IL19280008A IL192800A IL 192800 A IL192800 A IL 192800A IL 192800 A IL192800 A IL 192800A IL 19280008 A IL19280008 A IL 19280008A IL 192800 A IL192800 A IL 192800A
Authority
IL
Israel
Prior art keywords
fgf2
binding peptides
peptides
binding
Prior art date
Application number
IL192800A
Other languages
English (en)
Hebrew (he)
Other versions
IL192800A0 (en
Original Assignee
Sigma Tau Ind Farmaceuti
Tecnogen Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti, Tecnogen Spa filed Critical Sigma Tau Ind Farmaceuti
Publication of IL192800A0 publication Critical patent/IL192800A0/en
Publication of IL192800A publication Critical patent/IL192800A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
IL192800A 2006-01-24 2008-07-14 2fgf binding peptides and their use IL192800A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06001457 2006-01-24
PCT/EP2007/000538 WO2007085412A1 (en) 2006-01-24 2007-01-23 Fgf2-binding peptides and uses thereof

Publications (2)

Publication Number Publication Date
IL192800A0 IL192800A0 (en) 2009-02-11
IL192800A true IL192800A (en) 2015-04-30

Family

ID=37421191

Family Applications (1)

Application Number Title Priority Date Filing Date
IL192800A IL192800A (en) 2006-01-24 2008-07-14 2fgf binding peptides and their use

Country Status (19)

Country Link
US (1) US8076300B2 (enExample)
EP (1) EP1973944B1 (enExample)
JP (1) JP5427415B2 (enExample)
KR (1) KR101467453B1 (enExample)
CN (1) CN101384622B (enExample)
AU (1) AU2007209581B2 (enExample)
BR (1) BRPI0707239A8 (enExample)
CA (1) CA2637295C (enExample)
DK (1) DK1973944T3 (enExample)
EA (1) EA015339B1 (enExample)
ES (1) ES2575517T3 (enExample)
HR (1) HRP20160600T1 (enExample)
HU (1) HUE029212T2 (enExample)
IL (1) IL192800A (enExample)
MX (1) MX2008009289A (enExample)
PL (1) PL1973944T3 (enExample)
PT (1) PT1973944T (enExample)
SI (1) SI1973944T1 (enExample)
WO (1) WO2007085412A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204928A1 (en) * 2017-05-05 2018-11-08 Board Of Regents, The University Of Texas System Fgl2 monoclonal antibodies and their use in treating malignant tumors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
IT1317930B1 (it) * 2000-11-08 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
ITRM20020109A1 (it) * 2002-02-28 2003-08-28 Sigma Tau Ind Farmaceuti Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori.

Also Published As

Publication number Publication date
MX2008009289A (es) 2008-10-17
HRP20160600T1 (hr) 2016-07-01
KR101467453B1 (ko) 2014-12-01
CA2637295A1 (en) 2007-08-02
AU2007209581B2 (en) 2013-03-28
CN101384622B (zh) 2013-03-27
DK1973944T3 (en) 2016-06-27
SI1973944T1 (sl) 2016-07-29
BRPI0707239A8 (pt) 2018-01-30
ES2575517T3 (es) 2016-06-29
KR20080096794A (ko) 2008-11-03
IL192800A0 (en) 2009-02-11
WO2007085412B1 (en) 2007-10-11
JP2009523457A (ja) 2009-06-25
EA015339B1 (ru) 2011-06-30
BRPI0707239A2 (pt) 2011-04-26
HUE029212T2 (en) 2017-02-28
CN101384622A (zh) 2009-03-11
EP1973944A1 (en) 2008-10-01
PL1973944T3 (pl) 2016-09-30
PT1973944T (pt) 2016-07-07
EA200870188A1 (ru) 2009-02-27
US20090215689A1 (en) 2009-08-27
EP1973944B1 (en) 2016-05-11
WO2007085412A1 (en) 2007-08-02
CA2637295C (en) 2017-06-13
AU2007209581A1 (en) 2007-08-02
US8076300B2 (en) 2011-12-13
JP5427415B2 (ja) 2014-02-26

Similar Documents

Publication Publication Date Title
IL247617A0 (en) Peptide nanoparticles and their uses
ZA200810323B (en) Fkbp-l and uses thereof
GB0712670D0 (en) Isolated peptides and uses thereof
PL2064327T3 (pl) Dbait i ich zastosowania
GB0702020D0 (en) Peptides and their use
EP2017283A4 (en) Peptides
EP1976864A4 (en) NEW PEPTIDE AND ITS USE
IL185308A0 (en) Replikin peptides and uses thereof
ZA200903906B (en) Carboranylporphyrins and uses thereof
GB0702021D0 (en) Peptides and their use
IL195525A0 (en) Replikin peptides and uses thereof
GB0702022D0 (en) Peptides and their use
GB0621513D0 (en) Novel polypeptides and uses thereof
GB0604187D0 (en) Peptide and uses thereof
GB0607798D0 (en) Novel polypeptides and use thereof
PL2032708T3 (pl) Rekombinowane nowirabdowirusy i ich zastosowania
GB0618748D0 (en) Peptide
IL197675A0 (en) Peptides
IL192800A0 (en) Fgf2-binding peptides and uses thereof
GB0605774D0 (en) Peptide
GB0617564D0 (en) Peptides and methods
GB0612873D0 (en) Isolated peptides and uses thereof
GB0710813D0 (en) Peptides and uses thereof
PL378824A1 (pl) Peptyd i jego zastosowanie
GB0517813D0 (en) Peptides and uses thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees